Condition: Chronic Phase Chronic Myelogenous Leukemia · Sponsor: Medical College of Wisconsin
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.
This description comes directly from the study's public registry record.
Medical College of Wisconsin Cancer Center Clinical Trials Office · 414-805-8900 · cccto@mcw.edu
Ehab Atallah, MD · 414-805-4600 · eatallah@mcw.edu
Always discuss trial participation with your own doctor first.
| The Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04838041